Bru Espino, Antonio LeonardoBosch, R.Céspedes, M. V.Carmona Güedes, S.Pascual, E.Brú, I.Souto, J. C.2023-06-172023-06-172019-02-27Bru Espino, A. L., Bosch, R., Céspedes, M. V. et al. «Antitumoral Effect of Maintained Neutrophilia Induced by rhG-CSF in a Murine Model of Pancreatic Cancer». Scientific Reports, vol. 9, n.o 1, febrero de 2019, p. 2879. DOI.org (Crossref), https://doi.org/10.1038/s41598-019-39805-y.2045-232210.1038/s41598-019-39805-yhttps://hdl.handle.net/20.500.14352/13144Although the protumoral functions of polymorphonuclear neutrophils are well known, some now-forgotten studies report antitumoral roles for these cells. The present work examines the antitumoral effect of maintained neutrophilia induced via the injection of recombinant human granulocyte colony stimulating factor (rhG-CSF, 100 μg/kg/day) in a Panc-1 subcutaneous xenograft murine model of pancreatic cancer. This treatment was compared with gemcitabine administration (120 mg/kg every two days) and a saline control (n = 6–7 mice per group). Compared to the controls, both the rhG-CSF- and gemcitabine-treated mice showed significantly suppressed tumor growth by day 4 (p < 0.001 and p = 0.013 respectively). From a mean starting volume of 106.9 ± 3.1 mm3 for all treatment groups, the final mean tumor volumes reached were 282.0 ± 30.7 mm3 for the rhG-CSF-treated mice, 202.6 ± 18.1 mm3 for the gemcitabine-treated mice and 519.4 ± 62.9 mm3 for the control mice (p < 0.004 and p < 0.01, respectively, vs. control). The rhG-CSF-treated tumors showed higher percentage necrosis than those treated with gemcitabine (37.4 ± 4.6 vs. 7.5 ± 3.0; p < 0.001). This is the first report of a clear anti-tumoral effect of rhG-CSF when used in monotherapy against pancreatic cancer. Since rhG-CSF administration is known to be associated with very few adverse events, it may offer an attractive alternative in the clinical treatment of pancreatic cancer.engAtribución 3.0 Españahttps://creativecommons.org/licenses/by/3.0/es/journal articlehttps://doi.org/10.1038/s41598-019-39805-yhttps://www.nature.com/articles/s41598-019-39805-y#Abs1open access51:612.0751612.07Matemáticas aplicadasInmunología tumoralApplied mathematicsTumour immunologyMatemáticas (Matemáticas)InmunologíaOncología12 Matemáticas2412 Inmunología3201.01 Oncología